Dual antibody-guided drug delivery systems using MOF-PQDs nanocomposites for precise tumor diagnosis and combination therapy

Antibody-mediated MOF-CsPbX3 PQDs drug delivery systems facilitate the integration of chemotherapy, immunotherapy, and photodynamic therapy. Additionally, these systems function as PL/MRI contrast agents, enabling multimodal imaging for the diagnosis of various tumors. The antibody-mediated nanodrug systems are engineered to target tumors and emit distinct PL/MR signals, thereby allowing for precise diagnosis and simultaneous treatment of diverse malignant tumors. [Display omitted] •Porous MOF-PQDs nanocomposites serve as versatile platforms for drug delivery, multimodal imaging, and singlet oxygen photocatalysis.•Dual antibody of anti-HER2/anti-PD-L1 guided drug delivery system targets HER2 and PD-L1 overexpressed tumor cells.•Multimodal imaging using MRI and PL modes facilitates precise tumor diagnosis.•Codelivery of chemotherapeutic drug CPT and immunotherapy drugs of anti-HER2/anti-PD-L1.•Combination therapy integrating chemotherapy, immunotherapy, and photodynamic therapy for efficient tumor treatment. Due to their versatile capability to modulate both structure and function, MOF-based nanocomposites incorporating targeting ligands, bioimaging agents, and photosensitizers emerge as promising materials for drug delivery, diagnostic imaging probes, porous photocatalysts, and various biomedical applications. Herein, the CsPbX3 (X = Cl, Br, I) perovskite quantum dots (PQDs) with a wide range of photoluminescence (PL) spectra are incorporated onto the surface of a designed Gd-MOF, providing stable porous MOF-PQDs for applications as drug carriers, magnetic resonance imaging (MRI)/PL imaging probes and 1O2 photocatalysts. Anti-HER2 or anti-PD-L1 is conjugated on the nanocomposites through a divinylpyrimidine (DVP) induced covalent reaction. Antibodies against HER2 or PD-L1 serve dual roles, acting both as nanogates to regulate the delivery of camptothecin (CPT) chemotherapeutic drugs and as targeting components that specifically bind to antigens overexpressed in tumor cells. The constructed antibody-mediated MOF-PQDs function as both PL and MRI probes, facilitating multimodal imaging for diagnosing various tumors. The investigation effectively implements a personalized therapeutic regimen integrating chemotherapy, immunotherapy, and photodynamic therapy as required.